New maintenance drug shows promise for lymphoma patients with hepatitis b
NCT ID NCT04661943
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the drug chidamide as a maintenance treatment for 30 people with a type of lymphoma (DLBCL) who also have hepatitis B. All participants had finished chemotherapy and their cancer was in complete remission. The goal was to see if chidamide could help keep the cancer from coming back. The study was completed and looked at how long patients lived without their cancer returning.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Bethune Hospital of Jilin University
Changchun, Jilin, 130021, China